Psychosocial factors and interleukin-6 among women with advanced ovarian cancer

Cancer

Volumn 104, Issue 2, 2005, Pages 305-313

  Costanzo, Erin S ^a   Lutgendorf, Susan K ^a,b   Sood, Anil K ^c   Andersen, Barrie ^b   Sorosky, Joel ^d   Lubaroff, David M ^e  

^a E11 SSH   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HARTFORD HOSPITAL   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

Ascites; Depression; Interleukin 6; Ovarian carcinoma; Psychoneuroimmunology; Quality of life; Social support; Stress

Indexed keywords

CYTOKINE; INTERLEUKIN 6;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; ASCITES; BEHAVIOR; BLOOD LEVEL; CANCER STAGING; DEPRESSION; DISTRESS SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENTAL STRESS; MOOD; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPHYSIOLOGY; QUALITY OF LIFE; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; TUMOR LOCALIZATION;

ASCITIC FLUID; DEPRESSION; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OVARIAN NEOPLASMS; PSYCHOLOGY; QUALITY OF LIFE; SOCIAL SUPPORT; STRESS;

EID: 22244462683     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21147     Document Type: Article

References (57)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, editors. Practical gynecologic oncology. Baltimore: Williams & Wilkins; 1989:327-371.
3. Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol. 1995;59:231-242.
4. Bodurka-Bevers D, Basen-Engquist K, Camark CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78:302-308.
5. Lutgendorf SK, Anderson B, Larsen K, Buller RE, Sorosky JI. Cognitive processing, social support coping, and distress in gynecologic cancer patients. Cancer Res Ther Control. 1999; 8:123-137.
6. Lutgendorf SK, Anderson B, Sorosky JI, Buller RE, Lubaroff DM. Interleukin-6 and use of social support in gynecologic cancer patients. Int J Behav Med. 2000;7:127-142.
7. Van Snick J. Interleukin-6: An overview. Annu Rev Immunol 1990;8:253-278.
8. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990;50:6959-6965.
9. Ershler WB. Interleukin-6: A cytokine for gerontologists. Geriatr Biosci. 1993;41:176-181.
10. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997;66:27-30.
11. Scambia G, Testa U, Panici PB, et al. Interleukin-6 and serum levels in patients with gynecological tumors. Int J Cancer. 1994;57:318-323.
12. Moradi MM, Carson LF, Weinburg B, Haney AF, Twiggs LB, Ramakrishan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelia cancer. Cancer. 1993;72:2433-2440.
13. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration, and invasion of human ovarian carcinoma. Anticancer Res. 1997;17:337-342.
14. Wu S, Rodabaugh K, Martinez-Maza O, et al. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol. 1992;166:997-1007.
15. Scambia G, Testa U, Benedetti P, et al. Prognostic significance of IL-6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:352-356.
16. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martionez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-1043.
17. Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS. Exposure to physical and psychological stressors elevates plasma interleukin 6: Relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology. 1993;133: 2423-2530.
18. Lutgendorf SK, Garand L, Buckwalter KC, Tripp Reimer T, Hong S-Y, Lubaroff DM. Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J Gerontol A Biol Sci Med Sci. 1999;54A:M1-M6.
19. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA. 2003;100:9090-9095.
20. Maes M, Lin AH, Delmire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999;45:833-839.
21. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Rieman D, Berger M. Interleukin-6 plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 1997;247: 228-233.
22. Dentino AN, Pieper CF, Rao MK, et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc. 1999;47:6-11.
23. Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47:639-646.
24. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
25. Cohen HJ, Pieper CF, Harris T, Rao KMK, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997;52A:M201-M208.
26. Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seemen TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci. 2000;55A:M709-M715.
27. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-270.
28. Cannon J. Cytokines in aging and muscle homeostasis. J Gerontol A Biol Sci Med Sci. 1995;50:120-123.
29. Burger RA, Grosen EA, Ioli GR, et al. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res. 1995;15:255-260.
30. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73:1882-1888.
31. Cella D. Manual for the functional assessment of cancer therapy (FACT) and functional assessment of HIV infection (FAHI) measurement system. Chicago: Rush-Presbyterian St. Luke's Medical Center; 1994.
32. McNair DM, Lorr M, Droppleman LF. ETIS manual for the profile of mood states. San Diego: Educational and Industrial Testing Service; 1971.
33. Curran SL, Andrykowski MA, Studts JL. Short form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess. 1995;7:80-83.
34. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
35. Ensel WM. Measuring depression: the CES-D scale. Social support, life events, and depression. St. Louis: Academic Press; 1986.
36. Cutrona CE, Russell DW. The provisions of social relationships and adaptation to stress. In: Jones WH, Perlman D, editors. Advances in personal relationships, vol. 1. Greenwich: JAI Press; 1987:37-67.
37. Judd AM, MacLeod RM. Adrenocorticotropin hormone increases interleukin-6 release from rat adrenal zona glomerulosa cells. Endocrinology. 1992;130:1245-1254.
38. Navarra P, Tsagarakis S, Faria MS, Rees LH, Besser GM, Grossman AB. Interleukins-1 and -6 stimulate the release of corticotropin-releasing-hormone- 41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology. 1991;128:37-44.
39. Salas MA, Evans SW, Levell MJ, Whicher JT. Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol. 1990;79:470-473.
40. Seeman TE, McEwen BS. Impact of social environment characteristics on neuroendocrine regulation. Psychosom Med. 1996;58:459-471.
41. Seeman TE, Berkman LF, Blazer D, Rowe JW. Social ties and support and neuroendocrine function: The MacArthur studies of successful aging. Ann Behav Med. 1994;16:95-106.
42. Turner-Cobb JM, Sephton SE, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med. 2000;62:337-345.
43. Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R. Slowing of wound healing by psychological stress. Lancet. 1995;346:1194-1196.
44. Cohen S, Tyrrell D, Smith A. Psychological stress and susceptibility to the common cold. N Engl J Med. 1991;325:654-656.
45. Lutgendorf SK, Cole S, Costanzo ES, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9:4514-4521.
46. Wei LH, Kuo LM, Chen CA, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001;82:49-56.
47. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.
48. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736-741.
49. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998;105:83-107.
50. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74-81.
51. Janssen HLA, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21:241-243.
52. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cogntive side effects of interferon-alpha therapy. Semin Oncol. 1998;25(Suppl 1):39-47.
53. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993;50:681-689.
54. Pettingale BCW, Morris T, Greer S, Haybittle J. Mental attitudes to cancer: an additional prognostic factor. Lancet. 1985;1:750.
55. Ell K, Nishimoto R, Mediansky L, Mantell J, Hamovitchm M. Social relations, social support and survival among patients with cancer. J Psychosom Res. 1992;36:531-541.
56. Temoshok L, Heller B, Sagebiel RW, et al. The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. J Psychosom Res. 1985;29: 139-153.
57. Levy SM, Heberman RB, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med. 1991;17:67-75.